These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 6891727)

  • 1. Tolerance and reverse tolerance to haloperidol catalepsy induced by the difference of administration interval in mice.
    Masuda Y; Murai S; Itoh T
    Jpn J Pharmacol; 1982 Dec; 32(6):1186-8. PubMed ID: 6891727
    [No Abstract]   [Full Text] [Related]  

  • 2. Tolerance of haloperidol catalepsy.
    Ezrin-Waters C; Seeman P
    Eur J Pharmacol; 1977 Feb; 41(3):321-7. PubMed ID: 556989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitization versus tolerance to haloperidol-induced catalepsy: multiple determinants.
    Barnes DE; Robinson B; Csernansky JG; Bellows EP
    Pharmacol Biochem Behav; 1990 Aug; 36(4):883-7. PubMed ID: 2217518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosing time-dependent tolerance of catalepsy by repetitive administration of haloperidol in mice.
    Viyoch J; Ohdo S; Yukawa E; Higuchi S
    J Pharmacol Exp Ther; 2001 Sep; 298(3):964-9. PubMed ID: 11504791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of repeated haloperidol and apomorphine administration on the development of tolerance for catalepsy and dopamine receptor hypersensitivity in mice].
    Zharkovskiĭ AM; Matvienko OA; Nurk AM
    Biull Eksp Biol Med; 1984 Oct; 98(10):444-6. PubMed ID: 6541951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of tolerance and reverse tolerance to haloperidol- and SCH23390-induced cataleptic effects during withdrawal periods after long-term treatment.
    Ushijima I; Mizuki Y; Yamada M
    Pharmacol Biochem Behav; 1995 Feb; 50(2):259-64. PubMed ID: 7740066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential tolerance to cataleptic effects of SCH 23390 and haloperidol after repeated administration.
    Lappalainen J; Hietala J; Syvälahti E
    Psychopharmacology (Berl); 1989; 98(4):472-5. PubMed ID: 2570432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haloperidol-induced tolerance to morphine catalepsy.
    Ezrin-Waters C; Seeman P
    Life Sci; 1977 Aug; 21(3):419-22. PubMed ID: 561283
    [No Abstract]   [Full Text] [Related]  

  • 9. Conditioned tolerance to haloperidol- and droperidol-induced catalepsy.
    Nowak K; Welsch-Kunze S; Kuschinsky K
    Naunyn Schmiedebergs Arch Pharmacol; 1988 Apr; 337(4):385-91. PubMed ID: 3405313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of repeated testing on the incidence of haloperidol-induced catalepsy in mice.
    Iwata S; Izumi K; Shimizu T; Fukuda T
    Pharmacol Biochem Behav; 1989 Jul; 33(3):705-7. PubMed ID: 2587613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
    Tada M; Shirakawa K; Matsuoka N; Mutoh S
    Psychopharmacology (Berl); 2004 Oct; 176(1):94-100. PubMed ID: 15083255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerance phenomena with neuroleptics catalepsy, apomorphine stereotypies and striatal dopamine metabolism in the rat after single and repeated administration of loxapine and haloperidol.
    Asper H; Baggiolini M; Burki HR; Lauener H; Ruch W; Stille G
    Eur J Pharmacol; 1973 Jun; 22(3):287-94. PubMed ID: 4738903
    [No Abstract]   [Full Text] [Related]  

  • 13. [The role of the genotype in the cataleptogenic effect of neuroleptics].
    Skrinskaia IuA; Nikulina EM; Popova NK
    Eksp Klin Farmakol; 1992; 55(6):7-9. PubMed ID: 1363957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haloperidol catalepsy in grouped and isolated mice.
    Zetler G
    Pharmacology; 1975; 13(6):526-32. PubMed ID: 1241136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pavlovian conditional tolerance to haloperidol catalepsy: evidence of dynamic adaptation in the dopaminergic system.
    Poulos CX; Hinson R
    Science; 1982 Oct; 218(4571):491-2. PubMed ID: 6889765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dynamics of minute rhythms of catalepsy and role of a regimen of daily administration of haloperidol on the formation of tolerance].
    Arushanian EB; Popova AP; Shmygina EG
    Biull Eksp Biol Med; 1988 Jul; 106(7):58-61. PubMed ID: 3401581
    [No Abstract]   [Full Text] [Related]  

  • 17. Nicotine potentiates haloperidol-induced catalepsy and locomotor hypoactivity.
    Emerich DF; Zanol MD; Norman AB; McConville BJ; Sanberg PR
    Pharmacol Biochem Behav; 1991 Apr; 38(4):875-80. PubMed ID: 1871200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of haloperidol on changes in development of spontaneous catalepsy during subchronic injections of dopamine agonists and antagonists].
    Kozlovskiĭ VL
    Patol Fiziol Eksp Ter; 2012; (3):75-80. PubMed ID: 23072116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Further studies on the relationship between dopamine cell density and haloperidol-induced catalepsy.
    Hitzemann B; Dains K; Kanes S; Hitzemann R
    J Pharmacol Exp Ther; 1994 Nov; 271(2):969-76. PubMed ID: 7965819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-trial dopaminergic modulation of conditioned catalepsy: A single apomorphine induced increase/decrease in dopaminergic activation immediately following a conditioned catalepsy response can reverse/enhance a haloperidol conditioned and sensitized catalepsy response.
    Oliveira LR; Dias FRC; Santos BG; Silva JLL; Carey RJ; Carrera MP
    Behav Brain Res; 2016 Sep; 311():87-98. PubMed ID: 27173428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.